acute heart failure

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

atrial natriuretic peptide

nesiritide
NSGET (comparative trial), 2000     nesiritidecontrolLow risk of bias remark
NSGET (efficacy trial), 2000     nesiritideplaceboLow risk of bias negative
VMAC (intravenous neseritide), 2002      NCTnesiritideplaceboLow risk of bias remark
PRECEDENT, 2002      NCTnesiritidedobutamineExploratory remark
VMAC (24h), 2002      NCTnesiritidenitroglycerinRisk of bias negative

calcium sensitiser

levosimendan
REVIVE II, 2013      NCTlevosimendanplaceboLow risk of bias -
REVIVE-I, 2003       levosimendanplaceboExploratory remark
RUSSLAN, 2002   levosimendanplaceboLow risk of bias remark
SURVIVE, 2007    NCTlevosimendandobutamineLow risk of bias negative
CASINO   levosimendandobutamineLow risk of bias remark
LIDO, 2002   levosimendandobutamineLow risk of bias remark

diuretics

rolofylline
PROTECT, 2010    NCTrolofyllineplaceboLow risk of bias negative

endothelin receptor antagonist

not classified
VERITAS I, 2006      NCTtezosentanplaceboLow risk of bias remark
VERITAS II, 2007      NCTtezosentanplaceboLow risk of bias remark
RITZ-5, 2003     tezosentanplaceboLow risk of bias remark
RITZ 4 importé, 2003         tezosentanplaceboLow risk of bias remark
nesiritide
NSGET (comparative trial), 2000     nesiritidecontrolLow risk of bias remark
NSGET (efficacy trial), 2000     nesiritideplaceboLow risk of bias negative
PROACTION, 2003     nesiritideplaceboLow risk of bias negative
BNP-CARDS, 2007          NCTnesiritideplaceboLow risk of bias remark
FUSION 2, 2008        NCTnesiritideplaceboLow risk of bias remark
ASCEND-HF, 2011        NCTnesiritideplaceboLow risk of bias negative
VMAC (intravenous neseritide), 2002      NCTnesiritideplaceboLow risk of bias remark
PRECEDENT, 2002      NCTnesiritidedobutamineExploratory remark
VMAC (24h), 2002      NCTnesiritidenitroglycerinRisk of bias negative
FUSION 1, 2004    NCTnesiritidestandard careLow risk of bias remark

new drug under development

not classified
UNLOAD   -
CARRESS-HF     ultrafiltration -
AVOID HF    NCTultrafiltration -
B-CONVINCED, 2009    NCTbeta-blockade continuationdiscontinuation -
levosimendan
REVIVE II, 2013      NCTlevosimendanplaceboLow risk of bias -
REVIVE-I, 2003       levosimendanplaceboExploratory remark
RUSSLAN, 2002   levosimendanplaceboLow risk of bias remark
SURVIVE, 2007    NCTlevosimendandobutamineLow risk of bias negative
CASINO   levosimendandobutamineLow risk of bias remark
LIDO, 2002   levosimendandobutamineLow risk of bias remark
nesiritide
NSGET (comparative trial), 2000     nesiritidecontrolLow risk of bias remark
NSGET (efficacy trial), 2000     nesiritideplaceboLow risk of bias negative
PROACTION, 2003     nesiritideplaceboLow risk of bias negative
BNP-CARDS, 2007          NCTnesiritideplaceboLow risk of bias remark
FUSION 2, 2008        NCTnesiritideplaceboLow risk of bias remark
ASCEND-HF, 2011        NCTnesiritideplaceboLow risk of bias negative
VMAC (intravenous neseritide), 2002      NCTnesiritideplaceboLow risk of bias remark
PRECEDENT, 2002      NCTnesiritidedobutamineExploratory remark
VMAC (24h), 2002      NCTnesiritidenitroglycerinRisk of bias negative
FUSION 1, 2004    NCTnesiritidestandard careLow risk of bias remark
rolofylline
PROTECT, 2010    NCTrolofyllineplaceboLow risk of bias negative
serelaxin
Pre-RELAX-AHF, 2009      NCTserelaxinplaceboLow risk of bias -
RELAX-AHF, 2013      NCTserelaxinplacebo -

relaxin

serelaxin
Pre-RELAX-AHF, 2009      NCTserelaxinplaceboLow risk of bias -
RELAX-AHF, 2013      NCTserelaxinplacebo -

ultrafiltration

not classified
UNLOAD   -
CARRESS-HF     ultrafiltration -
AVOID HF    NCTultrafiltration -

vasopressin antagonist

tolvaptan
EVEREST Clinical Status , 2007      NCTtolvaptanplacebo -
EVEREST Outcome, 2007   tolvaptanplacebo -
Udelson, 2007      NCTtovalpanplaceboLow risk of bias suggesting